Charles River Laboratories Intl. Inc vs Honest Company Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $226.54 (market cap $11.14B), while Honest Company Inc trades at $4.03 (market cap $435.91M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 25.6× Honest Company Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Honest Company Inc nearer its low. Which is the better fit depends on your goals.
| CRL | HNST | |
|---|---|---|
Market Cap | $11.14B | $435.91M |
Sector | Health | Consumer Staples |
52-Week High | $233.60 | $4.95 |
52-Week Low | $145.57 | $2.10 |
Enterprise Value | $14.00B | $357.31M |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
HNST trades at $3.90, down 2.74% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting expectations, while revenue trends show volatility with 2025 revenue at $371.32M. Gross margins improved to 33.89%, but net income remains negative at -$15.69M for 2025. Positive cash flow from operations of $15.12M supports liquidity, though profitability challenges persist.
Outlook is mixed: analyst consensus leans hold (50%) with 30% buy ratings, citing improved fundamentals but limited upside. Key risks include sustained negative net margins and competitive pressures in personal care. The stock's high P/E of 48.83 suggests premium valuation despite lack of profits, requiring careful risk assessment for investment.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →